摘要
Epidemiological studies have revealed the association between diabetes and HCC. Nonalcoholic steatohepatitis (NASH) is apparently the key link between diabetes and HCC. Recently, it is noted that the effects of FGF19 and FGF21 on metabolism suggest that endocrine fibroblast growth factors (FGFs) and their derivatives carry great potential as novel therapeutic agents for metabolic conditions. The pharmacological application of FGF21/19 holds great promise as an effective therapeutic means for treating obesity and diabetes. New insights into FGF21 and FGF19/FGFR4 signaling may also offer a novel strategy to prevent and treat the subpopulation of HCC patients with metabolic disorders.
